Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 31 points (-0.2%) at 18,049 as of Monday, April 27, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,377 issues advancing vs. 1,612 declining with 170 unchanged.

The Drugs industry currently sits down 3.4% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the industry include

Akorn

(

AKRX

), down 20.6%,

Alnylam Pharmaceuticals

(

ALNY

), down 7.0%,

Mylan

(

MYL

), down 5.0%,

Incyte

(

INCY

), down 4.9% and

Vertex Pharmaceuticals

(

VRTX

), down 4.1%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Novo Nordisk A/S

(

NVO

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Novo Nordisk A/S is up $0.48 (0.8%) to $57.13 on heavy volume. Thus far, 1.3 million shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $57.03-$57.68 after having opened the day at $57.67 as compared to the previous trading day's close of $56.65.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $149.0 billion and is part of the health care sector. Shares are up 32.8% year-to-date as of the close of trading on Friday. Currently there are 2 analysts who rate Novo Nordisk A/S a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Novo Nordisk A/S

as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, notable return on equity, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Novo Nordisk A/S Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

GlaxoSmithKline

(

GSK

) is up $0.63 (1.3%) to $47.22 on heavy volume. Thus far, 3.5 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 3.5 million shares. The stock has ranged in price between $47.18-$47.75 after having opened the day at $47.43 as compared to the previous trading day's close of $46.59.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $124.0 billion and is part of the health care sector. Shares are up 8.3% year-to-date as of the close of trading on Friday. Currently there are 2 analysts who rate GlaxoSmithKline a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates

GlaxoSmithKline

as a

buy

. The company's strengths can be seen in multiple areas, such as its expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

GlaxoSmithKline Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Novartis

(

NVS

) is up $0.55 (0.5%) to $104.83 on average volume. Thus far, 791,231 shares of Novartis exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $104.64-$105.50 after having opened the day at $104.99 as compared to the previous trading day's close of $104.28.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Novartis has a market cap of $253.1 billion and is part of the health care sector. Shares are up 12.5% year-to-date as of the close of trading on Friday. Currently there are 6 analysts who rate Novartis a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Novartis

as a

buy

. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Novartis Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

null